Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus high-dose oxytocin for prevention of postpartum hemorrhage
IRCT20220122053780N1Phase 2Completed
- Sponsor
- Neyshabour University of Medical Sciences
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Neyshabour University of Medical Sciences. Primary endpoints: Postpartum hemorrhage measured in drape sheet, Admission hematocrit and 3 more. Started Dec 2021; status: completed.
02
Drugs
oxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on IRCT20220122053780N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220122053780N1.